Inventiva
Logotype for Inventiva S.A.

Inventiva (IVA) investor relations material

Inventiva Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Inventiva S.A.
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary11 Feb, 2026

Industry and market outlook

  • MASH field has seen recent clinical successes, two drug approvals, and three acquisitions, validating commercial potential.

  • Market opportunity estimated at over 15 million MASH patients in the U.S., with 375,000 addressable in F2 and F3 stages.

  • Diagnosis rates are rising due to new drug launches and increased disease awareness.

  • Many patients are expected to be on a GLP-1 backbone, with oral therapies layered on top.

  • Lanifibranor is positioned for use especially in diabetic F2/F3 patients due to metabolic benefits.

Company evolution and strategy

  • Underwent recapitalization in October 2024, extending cash runway and enabling strategic hires.

  • New leadership team with deep experience in drug approval and commercialization was assembled.

  • Focused on fundraising and building a team capable of executing late-stage trials and commercialization.

  • Cash runway extends to Q3 2027, contingent on positive phase III data and a third funding tranche.

  • Company is preparing for potential independent launch, with flexibility for strategic partnerships.

Clinical development and trial design

  • Phase III trial for lanifibranor is fully enrolled, targeting F2 and F3 MASH patients.

  • Trial design: randomized 1:1:1 to placebo, 800 mg, or 1200 mg daily, with 1,009 patients in main cohort.

  • Exploratory cohort includes about 400 F1/F4 patients, with 100 F4, to inform future outcomes trials.

  • Dropout rate is below 30%, within conservative powering assumptions.

  • Data cleaning and database lock are underway, with top-line data and NDA filing anticipated in the second half of the year.

What fibrosis effect size makes LANI a market winner?
How is LANI's weight gain managed or mitigated?
How will F4 exploratory data inform future trials?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Inventiva earnings date

Logotype for Inventiva S.A.
Q4 2025 TU16 Feb, 2026
Inventiva
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Inventiva earnings date

Logotype for Inventiva S.A.
Q4 2025 TU16 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of orally administered small molecule therapies for the treatment of serious diseases. The company's research primarily targets conditions related to fibrosis, lysosomal storage disorders, and oncology. Inventiva leverages its proprietary technology platform to identify and develop novel compounds that modulate nuclear receptors, transcription factors, and epigenetic regulation. The company's lead products are developed through strategic collaborations with other pharmaceutical companies, aiming to advance these therapies through clinical trials and regulatory approval. The company is headquartered in Daix, France, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage